

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

OMB APPROVAL  
OMB Number: 3235-0578  
Expires: April 30, 2010  
Estimated average burden  
hours per response: 10.5

FORM N-Q

QUARTERLY SCHEDULE OF PORTFOLIO HOLDINGS OF REGISTERED  
MANAGEMENT INVESTMENT COMPANY

Investment Company Act File Number: 811-21078

Registrant Name: PIMCO New York Municipal Income Fund II

Address of Principal Executive Offices: 1345 Avenue of the Americas  
New York, New York 10105

Name and Address of Agent for Service: Lawrence G. Altadonna  
1345 Avenue of the Americas  
New York, New York 10105

Registrant's telephone number, including area code: 212-739-3371

Date of Fiscal Year End: May 31, 2010

Date of Reporting Period: August 31, 2009

Form N-Q is to be used by management investment companies, other than small business investment companies registered on Form N-5 (§§ 239.24 and 274.5 of this chapter), to file reports with the Commission, not later than 60 days after the close of the first and third fiscal quarters, pursuant to rule 30b 1-5 under the Investment Company Act of 1940 (17 CFR 270.30b1-5). The Commission may use the information provided on Form N-Q in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-Q, and the Commission will make this information public. A registrant is not required to the collection of information contained in Form N-Q unless the Form displays a currently valid Office of Management and Budget ("OMB") control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549-2001. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. § 3507.

---

Item 1. Schedule of Investments

PIMCO New York Municipal Income Fund II Schedule of Investments

August 31, 2009 (unaudited)

Principal Amount (000)		Credit Rating (Moody's/S&P)	Value*
<b>NEW YORK MUNICIPAL BONDS &amp; NOTES—86.0%</b>			
\$2,400	Erie Cnty. Industrial Dev. Agcy. Rev., Orchard Park, Inc. Project, 6.00%, 11/15/36, Ser. A	NR/NR	\$1,631,904
4,120	Liberty Dev. Corp. Rev., Goldman Sachs Headquarters, 5.25%, 10/1/35 (f)	A1/A	4,028,248
3,000	5.25%, 10/1/35	A1/A	2,933,190
3,500	5.50%, 10/1/37	A1/A	3,524,850
1,850	Metropolitan Transportation Auth. Rev., 5.00%, 11/15/30, Ser. A (FSA)	Aa3/AAA	1,878,805
2,000	5.00%, 11/15/34, Ser. B	NR/AA	2,025,380
8,000	5.25%, 11/15/31, Ser. E	A2/A	8,067,280
7,000	5.35%, 7/1/31, Ser. B	A1/AAA	7,089,110
5,000	5.50%, 11/15/39, Ser. A	NR/AA	5,215,900
2,870	Mortgage Agcy. Rev., 4.75%, 10/1/27, Ser. 128	Aa1/NR	2,865,408
2,400	Nassau Cnty. Industrial Dev. Agcy. Rev., Amsterdam at Harborside, 6.70%, 1/1/43, Ser. A	NR/NR	1,873,896
1,100	New York City Health & Hospital Corp. Rev., Ser. A, 5.375%, 2/15/26	A1/A+	1,109,372
2,000	5.45%, 2/15/26	A1/A+	2,020,460
975	New York City Industrial Dev. Agcy. Rev., Eger Harbor Project, 4.95%, 11/20/32, Ser. A (GNMA)	NR/AA+	947,739
1,415	Liberty Interactive Corp., 5.00%, 9/1/35	Ba2/BB+	1,025,479
1,500	Queens Baseball Stadium, 6.50%, 1/1/46	Aa2/AAA	1,629,840
1,190	Staten Island Univ. Hospital Project, 6.45%, 7/1/32, Ser. C	Ba2/NR	1,036,811
1,500	United Jewish Appeal Fed. Project, 5.00%, 7/1/27, Ser. A Yankee Stadium, 5.00%, 3/1/31 (FGIC)	Baa3/BBB-	4,669,150
2,400	5.00%, 3/1/36 (NPFGC)	Baa1/A	2,159,664
4,900	7.00%, 3/1/49	Aa2/AAA	5,403,671
1,500	New York City Municipal Water Finance Auth. Rev., 5.25%, 6/15/40, Ser. EE	Aa3/AA+	1,578,420
500	Second Gen. Resolution, 5.00%, 6/15/39, Ser. GG-1	Aa3/AA+	506,920
9,000	New York City Transitional Finance Auth. Rev., 5.00%, 11/1/27, Ser. B	Aa1/AAA	9,283,140
5,000	5.25%, 1/15/39, Ser. S-3	A1/AA-	5,122,350
2,700	New York City Trust for Cultural Res. Rev., Julliard School, 5.00%, 1/1/34, Ser. A	Aa2/AA	2,789,262
7,785	Wildlife Conservation Society, 5.00%, 2/1/34 (FGIC-NPFGC)	Aa3/AA-	7,898,427
4,000	New York City, GO, 5.00%, 3/1/33, Ser. I	Aa3/AA	4,030,560
3,600	Port Auth. of New York & New Jersey Rev., 5.00%, 4/15/32, Ser. 125 (FSA)	Aa3/AAA	3,691,080
3,000	State Dormitory Auth. Rev., 5.00%, 3/15/38, Ser. A	NR/AAA	3,068,460
1,320	5.25%, 9/1/28 (Radian)	Baa3/BBB-	1,237,078
7,490	5.50%, 5/15/31, Ser. A (AMBAC)	A1/AA-	7,920,450
2,600	Catholic Health of Long Island, 5.10%, 7/1/34	Baa1/BBB+	2,239,770
2,000	Kaleida Health Hospital, 5.05%, 2/15/25 (FHA)	NR/AAA	2,014,980
5,300	Lenox Hill Hospital, 5.50%, 7/1/30 Memorial Sloan-Kettering Cancer Center, 5.00%, 7/1/35, Ser. 1	Ba1/NR	4,384,372
2,750	5.00%, 7/1/35, Ser. 1	Aa2/AA	2,734,022
2,000	5.00%, 7/1/36, Ser. A1	Aa2/AA	1,982,340
2,100	New York Univ., 5.00%, 7/1/38, Ser. A	Aa3/AA-	2,129,799
1,000	New York Univ. Hospital, 5.625%, 7/1/37, Ser. B	Baa2/BB+	865,090
5,850	North General Hospital, 5.00%, 2/15/25	NR/AA-	5,890,306
600	North Shore-Long Island Jewish Health System, 5.50%, 5/1/37, Ser. A (c)	Baa1/A-	588,018
5,000	Rochester General Hospital, 5.00%, 12/1/35 (Radian)	NR/BBB-	4,226,700

**PIMCO New York Municipal Income Fund II Schedule of Investments**

August 31, 2009 (unaudited)

Principal Amount (000)		Credit Rating (Moody's/S&P)	Value*
	Teachers College,		
\$4,270	5.00%, 7/1/32 (NPFGC)	A1/NR	\$4,303,263
3,000	5.50%, 3/1/39	A1/NR	3,062,250
3,000	Yeshiva Univ., 5.125%, 7/1/34 (AMBAC)	Aa3/NR	3,023,370
5,000	State Environmental Facs. Corp. Rev., 5.125%, 6/15/38, Ser. A	Aa1/AA+	5,180,650
1,000	State Thruway Auth. Rev., 4.75%, 1/1/29, Ser. G (FSA)	Aa3/AAA	1,012,630
6,000	State Urban Dev. Corp. Rev., 5.00%, 3/15/36, Ser. B-1 (f)	NR/AAA	6,127,680
	Triboro Bridge & Tunnel Auth. Rev.,		
710	5.00%, 1/1/32, Ser. A (FGIC-TCRS)	Aa2/AA-	717,874
5,000	5.25%, 11/15/34, Ser. A-2 (f)	Aa2/AA-	5,248,850
1,815	Ulster Cnty. Industrial Dev. Agcy. Rev., 6.00%, 9/15/37, Ser. A	NR/NR	1,301,954
2,000	Warren & Washington Cntys. Industrial Dev. Agcy. Rev.,		
	Glens Falls Hospital Project, 5.00%, 12/1/35, Ser. A (FSA)	Aa3/AAA	1,971,080
	Total New York Municipal Bonds & Notes (cost—\$168,393,545)		<u>168,823,147</u>
<b>OTHER MUNICIPAL BONDS &amp; NOTES—7.8%</b>			
<b>California—0.5%</b>			
1,000	Health Facs. Financing Auth. Rev.,		
	Catholic Healthcare West, 6.00%, 7/1/39, Ser. A	A2/A	<u>972,440</u>
<b>Florida—1.0%</b>			
1,000	Clearwater Water Rev., 5.25%, 12/1/39, Ser. A	A2/AA-	1,010,180
1,000	Miami-Dade Cnty. Rev., 5.50%, 10/1/36, Ser. A	A2/A-	<u>1,002,250</u>
			<u>2,012,430</u>
<b>Louisiana—0.5%</b>			
1,000	Parish of East Baton Rouge Rev., 5.25%, 2/1/39, Ser. A	A1/AA-	<u>1,019,290</u>
<b>Puerto Rico—5.8%</b>			
4,600	Aqueduct & Sewer Auth. Rev., 6.00%, 7/1/38, Ser. A	Baa3/BBB-	4,615,180
5,675	Children's Trust Fund Tobacco Settlement Rev., 5.625%, 5/15/43	Baa3/BBB	4,238,204
	Sales Tax Financing Corp. Rev., Ser. A,		
14,250	zero coupon, 8/1/54 (AMBAC)	A1/AA-	848,872
12,900	zero coupon, 8/1/56	Aa3/AA-	677,766
1,000	5.75%, 8/1/37	A2/A+	<u>1,027,310</u>
			<u>11,407,332</u>
	Total Other Municipal Bonds & Notes (cost—\$17,421,406)		<u>15,411,492</u>
<b>NEW YORK VARIABLE RATE NOTES (a)(b)(d)—3.1%</b>			
	JPMorgan Chase Putters/Drivers Trust Rev.,		
5,000	7.804%, 7/1/33, Ser. 3382	Aa1/NR	5,410,450
500	8.357%, 6/15/31, Ser. 3223	NR/AA+	560,635
	Total New York Variable Rate Notes (cost—\$5,393,508)		<u>5,971,085</u>
<b>CORPORATE BONDS &amp; NOTES (e)—2.5%</b>			
4,300	American General Finance Corp., 4.625%, 9/1/10	Baa3/BB+	3,744,204
1,900	CIT Group, Inc., 5.80%, 7/28/11	Ca/CC	<u>1,131,640</u>
	Total Corporate Bonds & Notes (cost—\$4,661,751)		<u>4,875,844</u>
<b>SHORT-TERM INVESTMENTS (e)—0.6%</b>			
<b>Corporate Notes—0.6%</b>			
700	American General Finance Corp., 0.945%, 10/2/09, FRN	Baa3/BB+	693,480
	International Lease Finance Corp., FRN,		
300	0.627%, 5/24/10	Baa3/BBB+	278,803
200	0.909%, 1/15/10	Baa3/BBB+	<u>193,616</u>
	Total Corporate Notes (cost—\$1,127,714)		<u>1,165,899</u>
	<b>Total Investments (cost—\$196,997,924)—100.0%</b>		<u><b>\$196,247,467</b></u>

## Notes to Schedule of Investments:

- \* Portfolio securities and other financial instruments for which market quotations are readily available are stated at market value. Market value is generally determined on the basis of last reported sales prices, or if no sales are reported, based on quotes obtained from a quotation reporting system, established market makers, or independent pricing services.

Portfolio securities and other financial instruments for which market quotations are not readily available or for which a development/event occurs that may significantly impact the value of a security, are fair-valued, in good faith, pursuant to procedures established by the Board of Trustees, or persons acting at their discretion pursuant to procedures established by the Board of Trustees. The Fund's investments are valued daily using prices supplied by an independent pricing service or dealer quotations, or by using the last sale price on the exchange that is the primary market for such securities, or the last quoted mean price for those securities for which the over-the-counter market is the primary market or for listed securities in which there were no sales. Independent pricing services use information provided by market makers or estimates of market values obtained from yield data relating to investments or securities with similar characteristics. Exchange-traded futures and options on futures are valued at the settlement price determined by the relevant exchange. Securities purchased on a when-issued or delayed-delivery basis are marked to market daily until settlement at the forward settlement value. Short-term securities maturing in 60 days or less are valued at amortized cost, if their original term to maturity was 60 days or less, or by amortizing their value on the 61st day prior to maturity, if the original term to maturity exceeded 60 days.

The prices used by the Fund to value securities may differ from the value that would be realized if the securities were sold and these differences could be material. The Fund's net asset value is normally determined as of the close of regular trading (normally, 4:00 p.m. Eastern time) on the New York Stock Exchange ("NYSE") on each day the NYSE is open for business.

- (a) Private Placement—Restricted as to resale and may not have a readily available market. Securities with an aggregate value of \$5,971,085, representing 3.1% of total investments.
- (b) 144A Security—Exempt from registration under Rule 144A of the Securities Act of 1933. These securities may be resold in transactions exempt from registration, typically only to qualified institutional buyers. Unless otherwise indicated, these securities are not considered to be illiquid.
- (c) Delayed-delivery security. To be settled/delivered after August 31, 2009.
- (d) Variable Rate Notes—Instruments whose interest rates change on specified date (such as a coupon date or interest payment date) and/or whose interest rates vary with changes in a designated base rate (such as the prime interest rate). The interest rate disclosed reflects the rate in effect on August 31, 2009.
- (e) All or partial amount segregated as collateral for reverse repurchase agreements.
- (f) Residual Interest Bonds held in Trust—Securities represent underlying bonds transferred to a separate securitization trust established in a tender option bond transaction in which the Fund acquired the residual interest certificates. These securities serve as collateral in a financing transaction.

### Glossary:

AMBAC—insured by American Municipal Bond Assurance Corp.

FGIC—insured by Financial Guaranty Insurance Co.

FHA—insured by Federal Housing Administration

FRN—Floating Rate Note. The interest rate disclosed reflects the rate in effect on August 31, 2009.

FSA—insured by Financial Security Assurance, Inc.

GNMA—insured by Government National Mortgage Association

GO—General Obligation Bond

NPFGC—insured by National Public Finance Guarantee Corporation

NR—Not Rated

Radian—insured by Radian Guaranty, Inc.

TCRS—Temporary Custodian Receipts

---

**Other Investments:**

(A) The weighted average daily balance of reverse repurchase agreements outstanding during the three months ended August 31, 2009 was \$5,910,695 at a weighted average interest rate of 0.82%. The total market value of underlying collateral (refer to the Schedule of Investments for positions segregated as collateral for reverse repurchase agreement) for open reverse repurchase agreements at August 31, 2009 was \$6,041,742. Open reverse repurchase agreements at August 31, 2009:

Counterparty	Rate	Trade Date	Maturity Date	Principal & Interest	Principal
Barclays Bank	0.75%	8/6/09	9/4/09	\$3,380,830	\$3,379,000
	1.50%	8/6/09	9/4/09	813,881	813,000
Credit Suisse First Boston	0.75%	8/17/09	9/17/09	407,127	407,000
					<u>\$4,599,000</u>

**Fair Value Measurements**—The Fund has adopted Financial Accounting Standards Board (“FASB”) Statement of Financial Accounting Standards No. 157, “Fair Value Measurements” (“FAS 157”). FAS 157 clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value and requires additional disclosures about the use of the fair value measurements. Under FAS 157, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e. the “exit price”) in an orderly transaction between market participants. The three levels of the fair value hierarchy under FAS 157 are described below:

- Level 1 – quoted prices in active markets for identical investments that the Fund has the ability to access
- Level 2 – valuations based on other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.) or quotes from inactive exchanges
- Level 3 – valuations based on significant unobservable inputs (including the Fund’s own assumptions in determining the fair value of investments)

The Fund has adopted FASB Staff Position No. 157-4, “Determining Fair Value When the Volume and Level of Activity for the Asset or Liability have Significantly Decreased and Identifying Transactions that are not Orderly” (“FAS-157-4”). FAS 157-4 provides guidance on determining when there has been a significant decrease in the volume and level of activity for an asset or liability, when a transaction is not orderly, and how that information must be incorporated into a fair value measurement. FAS 157-4 emphasizes that even if there has been a significant decrease in the volume and level of activity for an asset or liability and regardless of the valuation techniques used, the objective of a fair value measurement remains the same.

An investment asset’s or liability’s level within the fair value hierarchy is based on the lowest level input, individually or in the aggregate, that is significant to fair value measurement.

The valuation techniques used by the Fund to measure fair value during the three months ended August 31, 2009 maximized the use of observable inputs and minimized the use of unobservable inputs.

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

A summary of the inputs used at August 31, 2009, in valuing the Fund’s assets and liabilities is listed below by investment type.

	Level 1 - Quoted Prices	Level 2 - Other Significant Observable Inputs	Level 3 - Significant Unobservable Inputs	Value at 8/31/2009
<b>Investments in Securities - Assets</b>				
New York Municipal Bonds & Notes	—	\$ 168,823,147	—	\$ 168,823,147
Other Municipal Bonds & Notes	—	15,411,492	—	15,411,492
New York Variable Rate Notes	—	5,971,085	—	5,971,085
Corporate Bonds & Notes	—	4,875,844	—	4,875,844
Short-Term Investments	—	1,165,899	—	1,165,899
<b>Total Investments in Securities</b>	<b>—</b>	<b>\$ 196,247,467</b>	<b>—</b>	<b>\$ 196,247,467</b>

**Item 2. Controls and Procedures**

(a) The registrant's President & Chief Executive Officer and Treasurer, Principal Financial & Accounting Officer have concluded that the registrant's disclosure controls and procedures (as defined in Rule 30a-3(c) under the Act (17 CFR 270.30a-3(c))), are effective based on their evaluation of these controls and procedures as of a date within 90 days of the filing of this document.

(b) There were no significant changes in the registrant's internal controls over financial reporting (as defined in Rule 30a-3(d) under the Act (17 CFR 270.30a-3(d))) that occurred during the registrant's last fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

**Item 3. Exhibits**

(a) Exhibit 99.302 Cert. – Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Registrant: PIMCO New York Municipal Income Fund II

By /s/ Brian S. Shlissel  
President & Chief Executive Officer

Date: October 16, 2009

By /s/ Lawrence G. Altadonna  
Treasurer, Principal Financial & Accounting Officer

Date: October 16, 2009

Pursuant to the requirements of the Securities Exchange Act of 1934 and the Investment Company Act of 1940, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

By /s/ Brian S. Shlissel  
President & Chief Executive Officer

Date: October 16, 2009

By /s/ Lawrence G. Altadonna  
Treasurer, Principal Financial & Accounting Officer

Date: October 16, 2009

---

## CERTIFICATIONS

I, Brian S. Shlissel, certify that:

1. I have reviewed this report on Form N-Q of PIMCO New York Municipal Income Fund II;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
3. Based on my knowledge, the schedules of investments included in this report fairly present in all material respects the investments of the registrant as of the end of the fiscal quarter for which the report is filed;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report, based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 16, 2009

Signature & Title: /s/ Brian S. Shlissel  
Brian S. Shlissel, President & Chief Executive Officer

---

I, Lawrence G. Altadonna, certify that:

1. I have reviewed this report on Form N-Q of PIMCO New York Municipal Income Fund II;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report;
3. Based on my knowledge, the schedules of investments included in this report fairly present in all material respects the investments of the registrant as of the end of the fiscal quarter for which the report is filed;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 30a-3(c) under the Investment Company Act of 1940) and internal control over financial reporting (as defined in Rule 30a-3(d) under the Investment Company Act of 1940) for the registrant and have:
  - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of a date within 90 days prior to the filing date of this report, based on such evaluation; and
  - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and
  - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: October 16, 2009

Signature & Title: /s/ Lawrence G. Altadonna  
Lawrence G. Altadonna, Treasurer, Principal Financial & Accounting Officer

---